Rocket Pharmaceuticals, Inc.
HealthcareNASDAQ:RCKT · NASDAQ Global Market
+$0.09 today
Vol 2.42M · Avg 3.13M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$223.1M +13.8% | -$258.7M -5.4% | -$245.6M -10.7% | -$221.9M -31.2% | -$169.1M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $11.0M +17.6% | $9.4M +32.1% | $7.1M +13.3% | $6.3M +16.6% | $5.4M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $3.1M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $37.1M -15.6% | $43.9M +11.5% | $39.4M +27.1% | $31.0M +6.1% | $29.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$8.3M -532.4% | $1.9M -85.7% | $13.5M +121.5% | $6.1M +279.4% | -$3.4M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 | $0 -100.0% | $9.7M +300.4% | -$4.8M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$8.3M -532.4% | $1.9M -85.7% | $13.5M +474.0% | -$3.6M -349.7% | $1.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$6.7M -7.8% | -$6.2M +33.3% | -$9.3M -2608.9% | $370.0K -97.3% | $13.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$190.0M +9.4% | -$209.7M -7.6% | -$194.9M -9.4% | -$178.1M -47.0% | -$121.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$440.0K +92.5% | -$5.9M +64.4% | -$16.5M -91.1% | -$8.6M -11.7% | -$7.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 -100.0% | $42.7M +44874.7% | $95.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$276.6M -12.5% | -$245.9M +37.1% | -$390.9M -3.9% | -$376.3M -53.1% | -$245.9M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $380.8M -0.7% | $383.5M +24.0% | $309.3M +13.4% | $272.9M +0.2% | $272.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 +100.0% | -$95.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $103.8M -21.2% | $131.7M +234.3% | -$98.1M -41.5% | -$69.3M -467.7% | $18.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $35.0K | $0 -100.0% | $139.0K -19.2% | $172.0K -14.4% | $201.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 -100.0% | $185.7M -10.9% | $208.4M +34.2% | $155.3M +312.2% | $37.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 +100.0% | -$47.0K | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $113.0K | $0 +100.0% | -$132.0K +23.3% | -$172.0K +14.4% | -$201.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $148.0K -99.9% | $185.7M -10.9% | $208.4M +34.2% | $155.3M +312.1% | $37.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$86.1M -179.9% | $107.7M +227.4% | -$84.6M +8.2% | -$92.2M -42.6% | -$64.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$190.5M +11.7% | -$215.6M -2.0% | -$211.4M -13.2% | -$186.8M -44.9% | -$128.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
SEC Filings
Recent regulatory filings
No filings found.
Does RCKT generate free cash flow?
Rocket Pharmaceuticals, Inc. (RCKT) generated -$190,454,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does RCKT produce?
Operating cash flow was -$190,014,000.00, before capital expenditures of $440,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.